Exelixis Inc Research and Development Asset Acquired Other than Through Business Combination, Written-off
Exelixis Inc (EXEL) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $10.60 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-05
- Exelixis Inc research and development asset acquired other than through business combination, written-off for the quarter ending 2026-07-03 was $8.57M, a 1043.33% increase year-over-year.
- Exelixis Inc research and development asset acquired other than through business combination, written-off for the quarter ending 2026-04-03 was $2.02M.
- Exelixis Inc research and development asset acquired other than through business combination, written-off for the quarter ending 2026-01-02 was $5.00M, a 74.36% decline year-over-year.
- Exelixis Inc research and development asset acquired other than through business combination, written-off for the quarter ending 2025-10-03 was $6.25M, a 43.19% decline year-over-year.
- Exelixis Inc research and development asset acquired other than through business combination, written-off for fiscal 2026 was $12.00M, a 76.36% decline from fiscal 2025.
- Exelixis Inc research and development asset acquired other than through business combination, written-off for fiscal 2025 was $50.75M, a 60.51% decline from fiscal 2023.
- Exelixis Inc research and development asset acquired other than through business combination, written-off for fiscal 2023 was $128.50M, a 19.81% increase from fiscal 2022.
- Exelixis Inc research and development asset acquired other than through business combination, written-off for fiscal 2022 was $107.25M, a 666.07% increase from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2026-07-03 | $8.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.60M 10-Q · filed 2026-08-05 | $15.60M derived: sum of 3 quarters · filed 2026-08-05 | $21.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $2.02M 10-Q · filed 2026-05-05 | $7.03M derived: sum of 2 quarters · filed 2026-05-05 | $13.27M derived: sum of 3 quarters · filed 2026-05-05 | $14.02M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $11.25M derived: sum of 2 quarters · filed 2026-02-10 | $12.00M derived: sum of 3 quarters · filed 2026-08-05 | $12.00M 10-K · filed 2026-02-10 |
| 2025-10-03 | $6.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.00M derived: sum of 2 quarters · filed 2026-08-05 | $7.00M 10-Q · filed 2025-11-04 | $26.50M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $750.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $750.00K 10-Q · filed 2026-08-05 | $20.25M derived: sum of 3 quarters · filed 2026-08-05 | $31.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $0.00 10-Q · filed 2026-05-05 | $19.50M derived: sum of 2 quarters · filed 2026-05-05 | $30.50M derived: sum of 3 quarters · filed 2026-05-05 | $31.25M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $19.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $30.50M derived: sum of 2 quarters · filed 2026-02-10 | $31.25M derived: sum of 3 quarters · filed 2026-02-10 | $50.75M 10-K · filed 2026-02-10 |
| 2024-09-27 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $11.75M derived: sum of 2 quarters · filed 2025-11-04 | $31.25M 10-Q · filed 2025-11-04 | $31.25M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $750.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $20.25M 10-Q · filed 2025-07-28 | $20.25M derived: sum of 3 quarters · filed 2026-02-10 | $111.25M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $19.50M 10-Q · filed 2025-05-13 | $19.50M derived: sum of 2 quarters · filed 2026-02-10 | $110.50M derived: sum of 3 quarters · filed 2026-02-10 | $111.50M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $91.00M derived: sum of 2 quarters · filed 2026-02-10 | $92.00M derived: sum of 3 quarters · filed 2026-02-10 | $128.50M 10-K · filed 2026-02-10 |
| 2023-09-29 | $91.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $92.00M derived: sum of 2 quarters · filed 2024-10-29 | $128.50M 10-Q · filed 2024-10-29 | $231.25M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $37.50M 10-Q · filed 2024-08-06 | $140.25M derived: sum of 3 quarters · filed 2025-02-11 | $143.25M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $36.50M 10-Q · filed 2024-04-30 | $139.25M derived: sum of 2 quarters · filed 2025-02-11 | $142.25M derived: sum of 3 quarters · filed 2025-02-11 | |
| 2022-12-30 | $102.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $105.75M derived: sum of 2 quarters · filed 2025-02-11 | $107.25M 10-K · filed 2025-02-11 | |
| 2022-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $4.50M 10-Q · filed 2023-11-01 | ||
| 2022-07-01 | $1.50M 10-Q · filed 2023-08-01 | |||
| 2021-12-31 | $14.00M 10-K · filed 2024-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |